Endocrine Abstracts

Introduction: In humans, prostate PDE5 expression was prominently localized in the endothelial and smooth muscle cells of the vascular bed, suggesting a possible action of PDE5 inhibitors on prostate blood flow.Aim: To investigate PDE5 expression in human and rat lower urinary tract (LUT) tissues and determine the effects of PDE5 inhibition with tadalafil on prostatic blood perfusion.Main outcome measures: Human vesicular-deferenti...

BXL-628 is a non-hypercalcemic calcitriol analog successfully tested in a phase IIa trial for benign prostate hyperplasia therapy. Because part of low urinary tract symptoms (LUTS) are generated by overactive bladder (OAB) and bladder expresses the calcitriol receptor (VDR), we investigated the BXL-628 effects on bladder contractility and RhoA/ROK signalling activated in OAB, by in vivo (2-weeks; 30 mcg/Kg, Sprague-Dawley, SD, and spontaneously hypertensive rats, SHR) a...